Conflict of Interest
Statement
None declared.
1. Canio WC. Polypharmacy in Older Adults. Clin Geriatr Med .
2022;38(4):621-625. doi:10.1016/j.cger.2022.05.004
2. Jyrkkä J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Patterns
of drug use and factors associated with polypharmacy and excessive
polypharmacy in elderly persons: Results of the kuopio 75 study: A
cross-sectional analysis. Drugs and Aging . 2009;26(6):493-503.
doi:10.2165/00002512-200926060-00006
3. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey G. What is
polypharmacy? A systematic review of definitions. BMC Geriatr .
2017;17(1):230. doi:10.1186/s12877-017-0621-2
4. O’Donnell LK, Ibrahim K. Polypharmacy and deprescribing: challenging
the old and embracing the new. BMC Geriatr . 2022;22(1):734.
doi:10.1186/s12877-022-03408-6
5. Baruth JM, Gentry MT, Rummans TA, Miller DM, Burton MC. Polypharmacy
in older adults: the role of the multidisciplinary team. Hosp
Pract . 2020;48(sup1):56-62. doi:10.1080/21548331.2019.1706995
6. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people:
the prescribing cascade. BMJ . 1997;315(7115):1096-1099.
doi:10.1136/bmj.315.7115.1096
7. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate
polypharmacy: the process of deprescribing. JAMA Intern Med .
2015;175(5):827-834. doi:10.1001/jamainternmed.2015.0324
8. Beuscart J-BB, Pont LG, Thevelin S, et al. A systematic review of the
outcomes reported in trials of medication review in older patients: the
need for a core outcome set. Br J Clin Pharmacol .
2017;83(5):942-952. doi:10.1111/bcp.13197
9. Dalin DA, Frandsen S, Madsen GK, Vermehren C. Exploration of Symptom
Scale as an Outcome for Deprescribing: A Medication Review Study in
Nursing Homes. Pharmaceuticals . 2022;15(5):1-13.
doi:10.3390/ph15050505
10. Ali MU, Sherifali D, Fitzpatrick-Lewis D, et al. Interventions to
address polypharmacy in older adults living with multimorbidity.Can Fam Physician . 2022;68(7):E215-E226.
doi:10.46747/cfp.6807e215
11. Pedersen KM, Andersen JS, Snødergaard J. General practice and
primary health care in Denmark. J Am Board Fam Med .
2012;25(SUPPL. 1):34-38. doi:10.3122/jabfm.2012.02.110216
12. Pottegård A, Olesen M, Christensen B, Christensen MB, Hallas J,
Rasmussen L. Who prescribes drugs to patients: A Danish register-based
study. Br J Clin Pharmacol . 2021;87(7):2982-2987.
doi:10.1111/bcp.14691
13. WHO. WHO. Global campaign: Medication Without Harm. Published 2019.
https://www.who.int/patientsafety/medication-safety/campaign/en/
14. Tveden-Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J.
BCPT policy for experimental and clinical studies. Basic Clin
Pharmacol Toxicol . 2021;128(1):4-8. doi:10.1111/bcpt.13492
15. General Data Protection Regulation (GDPR) Compliance Guidelines.
https://gdpr.eu/
16. Praktiserende Lægers Organisation. Læge- Og
Praksispopulationen 1977-2020. Nøgletal Fra Medlemsregisteret [General
Practioners and General Practice Clinics 1977-2020. Key Figures from the
Member Register. ; 2020.
17. Garfinkel D. Poly-de-prescribing to treat polypharmacy: efficacy and
safety. Ther Adv Drug Saf . 2018;9(1):25-43.
doi:10.1177/2042098617736192
18. Rankin A, Cadogan CA, Patterson SM, et al. Interventions to improve
the appropriate use of polypharmacy for older people. Cochrane
database Syst Rev . 2018;9(9):CD008165.
doi:10.1002/14651858.CD008165.pub4
19. Thillainadesan J, Gnjidic D, Green S, Hilmer SN. Impact of
Deprescribing Interventions in Older Hospitalised Patients on
Prescribing and Clinical Outcomes: A Systematic Review of Randomised
Trials. Drugs Aging . 2018;35(4):303-319.
doi:10.1007/s40266-018-0536-4
20. Kua C-H, Mak VSL, Huey Lee SW. Health Outcomes of Deprescribing
Interventions Among Older Residents in Nursing Homes: A Systematic
Review and Meta-analysis. J Am Med Dir Assoc .
2019;20(3):362-372.e11. doi:10.1016/j.jamda.2018.10.026
21. Almutairi H, Stafford A, Etherton-Beer C, Flicker L. Optimisation of
medications used in residential aged care facilities: A systematic
review and meta-analysis of randomised controlled trials. BMC
Geriatr . 2020;20(1):1-19. doi:10.1186/s12877-020-01634-4
22. Thio SL, Nam J, Van Driel ML, Dirven T, Blom JW. Effects of
discontinuation of chronic medication in primary care: A systematic
review of deprescribing trials. Br J Gen Pract .
2018;68(675):e663-e672. doi:10.3399/bjgp18X699041
23. Ulley J, Harrop D, Ali A, Alton S, Fowler Davis S. Deprescribing
interventions and their impact on medication adherence in
community-dwelling older adults with polypharmacy: A systematic review.BMC Geriatr . 2019;19(1):1-13. doi:10.1186/s12877-019-1031-4
24. Ibrahim K, Cox NJ, Stevenson JM, Lim S, Fraser SDS, Roberts HC. A
systematic review of the evidence for deprescribing interventions among
older people living with frailty. BMC Geriatr . 2021;21(1):1-16.
doi:10.1186/s12877-021-02208-8
25. Garfinkel D, Mangin D. Feasibility study of a systematic approach
for discontinuation of multiple medications in older adults: Addressing
polypharmacy. Arch Intern Med . 2010;170(18):1648-1654.
doi:10.1001/archinternmed.2010.355
26. Van Der Velde N, Stricker BHC, Pols HAP, Van Der Cammen TJM. Risk of
falls after withdrawal of fall-risk-increasing drugs: A prospective
cohort study. Br J Clin Pharmacol . 2007;63(2):232-237.
doi:10.1111/j.1365-2125.2006.02736.x
27. Potter K, Flicker L, Page A, Etherton-Beer C. Deprescribing in Frail
Older People: A randomised controlled trial. PLoS One .
2016;11(3):1-21. doi:10.1371/journal.pone.0149984
28. Garfinkel D, Zur-Gil S, Ben-Israel J. The war against polypharmacy:
A new cost-effective geriatric-positive approach for improving drug
therapy in disabled elderly people. Isr Med Assoc J .
2007;9(6):430-434.
29. Reeve E, Moriarty F, Nahas R, Turner JP, Kouladjian O’Donnell L,
Hilmer SN. A narrative review of the safety concerns of deprescribing in
older adults and strategies to mitigate potential harms. Expert
Opin Drug Saf . 2018;17(1):39-49. doi:10.1080/14740338.2018.1397625
30. Verdoorn S, Kwint HF, Blom JW, Gussekloo J, Bouvy ML. Effects of a
clinical medication review focused on personal goals, quality of life,
and health problems in older persons with polypharmacy: A randomised
controlled trial (DREAMER-study). PLoS Med . 2019;16(5):1-18.
doi:10.1371/journal.pmed.1002798
31. McCarthy C, Clyne B, Boland F, et al. GP-delivered medication review
of polypharmacy, deprescribing, and patient priorities in older people
with multimorbidity in Irish primary care (SPPiRE Study): A cluster
randomised controlled trial. PLoS Med . 2022;19(1):1-19.
doi:10.1371/journal.pmed.1003862
32. Salisbury C, Man MS, Bower P, et al. Management of multimorbidity
using a patient-centred care model: a pragmatic cluster-randomised trial
of the 3D approach. Lancet . 2018;392(10141):41-50.
doi:10.1016/S0140-6736(18)31308-4
33. Schäfer I, Kaduszkiewicz H, Mellert C, et al. Narrative
medicine-based intervention in primary care to reduce polypharmacy:
Results from the cluster-randomised controlled trial MultiCare AGENDA.BMJ Open . 2018;8(1):1-14. doi:10.1136/bmjopen-2017-017653
34. Trenaman SC, Kennie-Kaulbach N, d’Entremont-MacVicar E, et al.
Implementation of pharmacist-led deprescribing in collaborative primary
care settings. Int J Clin Pharm . Published online 2022.
doi:10.1007/s11096-022-01449-w
35. Wang T, Tan JYB, Liu XL, Zhao I. Barriers and enablers to
implementing clinical practice guidelines in primary care: an overview
of systematic reviews. BMJ Open . 2023;13(1):e062158.
doi:10.1136/bmjopen-2022-062158
36. Baumgartner A, Kunkes T, Clark CM, et al. Opportunities and
recommendations for improving medication safety: Understanding the
medication management system in primary care through an abstraction
hierarchy. JMIR Hum Factors . 2020;7(3). doi:10.2196/18103
37. Macias FM, Ramsay RE, Rowan AJ. Recruitment and retention in
clinical trials of the elderly. Int Rev Neurobiol .
2007;81:265-272. doi:10.1016/S0074-7742(06)81017-2
38. Reilev M, Lundby C, Jensen J, Larsen SP, Hoffmann H, Pottegård A.
Morbidity and mortality among older people admitted to nursing home.Age Ageing . 2019;49(1):67-73. doi:10.1093/ageing/afz136